Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,051 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Initial blood draw Clear all
Terminated Phase 1 Interventional

Cyclophosphamide and Alemtuzumab In Lymphoma

NCT03132584
View directory record Official record
Conditions
Non Hodgkin Lymphoma, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Interventions
Cyclophosphamide, Alemtuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Sep 12, 2026, 2:19 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

NCT01605318
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions
Labetuzumab Govitecan (LG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

NCT00354978
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Leucovorin, Irinotecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

NCT01665768
View directory record Official record
Conditions
CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL), Transformed Lymphoma/DLBCL/PMBCL, Hodgkin's Disease, Gray Zone Lymphoma
Interventions
Everolimus, Rituximab
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Center for Stroke Disparities Solution - Community Transitions Intervention

NCT01918891
View directory record Official record
Conditions
Hypertension, Stroke, Transient Ischemic Attack
Interventions
Nurse Practitioner Only, Nurse Practitioner + Health Coach
Behavioral
Lead sponsor
Visiting Nurse Service of New York
Other
Eligibility
21 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Results available

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

NCT01172418
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Alemtuzumab, Daclizumab, Thymoglobulin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

NCT00890500
View directory record Official record
Conditions
Hematologic Malignancies, Allogeneic Stem Cell Transplantation
Interventions
Fludarabine, Melphalan, Antithymocyte Globulin, Sirolimus, Tacrolimus
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00828009
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, Tecemotide, carboplatin, cyclophosphamide, paclitaxel, radiotherapy
Biological · Drug · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
88
States / cities
Palo Alto, California • Stanford, California • Macon, Georgia + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 12, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

NCT04943848
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
rHSC-DIPGVax, Balstilimab, Zalifrelimab
Biological · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

NCT00235391
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 12, 2026, 2:19 PM EDT
Completed No phase listed Observational

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index

NCT01701050
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Blood collection
Other
Lead sponsor
Janssen Diagnostics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

NCT03524326
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma
Interventions
Lenvatinib Pill, Cetuximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 12, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT

NCT00586274
View directory record Official record
Conditions
FANCONI ANEMIA
Interventions
CD34 selected haploidentical PBSCT, Fludarabine, T cell infusion, Campath 1h, anti-CD45
Procedure · Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 12, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Cardiometabolic Screening Program

NCT05386719
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer
Interventions
Prescreening, Screening and Enrollment, Baseline, Interpret BMI, Interpret HbA1c, Interpret lipid panel and assess other risk factors, Assess 10 year risk of cardiovascular event, Recommendations, Follow-Up
Other · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitric Oxide and the Autonomic Nervous System

NCT00178919
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure
Interventions
L-NMMA, Trimethaphan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112294
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Paclitaxel (Taxane), Docetaxel (Taxane), Carboplatin, Cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
124
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 12, 2026, 2:19 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Sep 12, 2026, 2:19 PM EDT
Not listed Phase 3 Interventional

Non-inferiority Trial of Oral Tranexamic Acid vs. Intravenous Tranexamic Acid in Joint Replacement Surgery

NCT02438566
View directory record Official record
Conditions
Osteoarthritis, Blood Loss, Surgical, Blood Loss, Postoperative
Interventions
Tranexamic Acid (Oral), Tranexamic Acid (Intravenous)
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 12, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional Results available

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Chemotherapy
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2015 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

NCT02538666
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab, Ipilimumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
28
States / cities
Sacramento, California • New Haven, Connecticut • Fort Myers, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Blood Flow Regulation in Individuals With Down Syndrome - Training Study

NCT04854122
View directory record Official record
Conditions
Down Syndrome
Interventions
Combined exercise intervention, Usual care / Sham intervention
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 12, 2026, 2:19 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

NCT03719131
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
Interventions
Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 12, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00425646
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, imatinib mesylate
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 12, 2026, 2:19 PM EDT